ABSTRACT
PURPOSE: In order to assess the usefulness of serum ferritin as a marker of disease activity and prognostic factor in pediatric malignancy, serum ferritin levels were measured. METHODS: Peripheral blood samplings for ferritin level were made at presentation, in remission following therapy, and in relapse in 95 children with malignancy admitted to the Department of Pediatrics, Kosin University Gospel Hospital between January, 1986 and August, 1995. The patients were comprised of 35 acute lymphoblastic leukemia(ALL), 17 acute myelogenous leukemia(AML), 20 non- Hodgkin's lymphoma(NHL) and 23 neuroblastoma(NB). RESULTS: The mean values of serum ferritin at presentation were 465.3+/-53.9 ng/mL in ALL, 468.9+/-69.4 ng/mL in AML, 274.1+/-69.2 ng/mL in NHL and 337.3+/-64.4 ng/mL in NB. Those values were increased significantly compared to the mean of 20 control children(69.5+/-12.9 ng/mL). The mean values of serum ferritin concentration in remission stage(first, second, and third remission) tend to be lower compared to those in the active stage(at presentation, first relapse and second relapse). But these differences reached a statistical significance only in patients with ALL when the mean values of the active stage were compared to those checked in the remission stage over 12 months(P= 0.0002). Comparison of overall survival according to initial serum ferritin levels(below and above 200 ng/mL) did not show any significant difference in ALL, AML and NHL. However, there was a borderline relationship in NB(relative risk 3.12, P=0.06). CONCLUSION: The study showed that normalization of serum ferritin levels were found in ALL who had continuous, complete remission for more than 12 months. And patients with lower serum ferritin levels were not associated with better survival except in patients with NB in which the lower ferritin group showed borderline significance.
Subject(s)
Child , Humans , Ferritins , Leukemia , Lymphoma , Neuroblastoma , Pediatrics , Prognosis , RecurrenceABSTRACT
BACKGROUND: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. isolates are clinically resistant to all the beta-lactams except for carbapenems. The most important task facing clinical microbiologists today is the reliable detection of ESBL-producing microorganisms. There is currently a little reliable methods designed specifically for the detection of ESBLs in isolates of E. coli and Klebsiella spp. that can be performed easily in a clinical laboratory. This study was designed to evaluate the ability of the Vitek GNS 121 card to detect the ESBL-producing E. coli and Klebsiella spp. METHODS: One hundred and twenty-two isolates of E. coli, 141 of K. pneumoniae, and 3 of K. oxytoca from patients of the Kosin Medical Center, Pusan, Korea were tested. Antimicrobial susceptibilities were tested by the disk diffusion method. And the double disk synergy (DDS) test and the Vitek GNS 121 card determined the ESBL-production. RESULTS: Among the 135 DDS-positive isolates (K. peumoniae, 104; E. coli, 28; K. oxytoca, 3), 131 isolates (K. pneumoniae, 103; E. coli, 25; K. oxytoca, 3) showed positive results with the Vitek GNS 121 card as well. And all the isolates of K. pneumoniae (37) and E. coli (94) showed negative results with both the DDS test and the Vitek GNS 121 card except for 1 isolate of E. coli. The Vitek GNS 121 card showed 97% ESBL detection-sensitivity, 99% specificity and 99% positive predictive value. Three isolates of E. coli and 1 of K. pneumoniae resistant to cefoxitin showed positive results with the DDS test but showed negative results with the Vitek GNS 121 card. CONCLUSIONS: The Vitek GNS 121 card seems to be adequate for routine use in the detection of ESBL-producing isolates of E. coli and Klebsiella in clinical microbiology laboratories. Also, additional evaluation should be taking place on its detection ability for other members of the ESBL-producing Enterobacteriaceae.